US Joint Guarantee Callable Healthcare & Pharmaceuticals Corporate Bond Yields (USD)
Fitted spot curve as of 2026-07-27
https://bondscovery.com/yield-curve/usd-corporate-joint-guarantee-healthcare-pharmaceuticals-callable
US Joint Guarantee Callable Healthcare & Pharmaceuticals Corporate Bond Yields (USD) as of 2026-07-27: 10Y at 5.41%, fitted curve 1M–30Y (4.70%–5.86%), 84 bonds. Live chart, constituents and forward rates on bondScovery.
| Maturity | Fitted yield | Forward rate |
|---|---|---|
| 1M | 4.70% | — |
| 6M | 4.71% | 4.71% |
| 9M | 4.72% | 4.74% |
| 18M | 4.75% | 4.78% |
| 2Y | 4.77% | 4.84% |
| 3Y | 4.82% | 4.93% |
| 4Y | 4.89% | 5.07% |
| 5Y | 4.96% | 5.25% |
| 6Y | 5.04% | 5.46% |
| 7Y | 5.13% | 5.68% |
| 8Y | 5.23% | 5.89% |
| 9Y | 5.32% | 6.08% |
| 10Y | 5.41% | 6.23% |
| 15Y | 5.72% | 6.34% |
| 20Y | 5.83% | 6.14% |
| 25Y | 5.85% | 5.96% |
| 30Y | 5.86% | 5.89% |
2Y, 10Y and the 10Y−2Y spread over time
The 2-year yield is 4.77% and the 10-year 5.41%, a 10Y−2Y spread of +64 bp — positively sloped — as of 2026-07-27. The chart and table below track how they have moved.
Fitted 2Y and 10Y yields and their spread, sampled one build date per month. See all inverted curves today →
| Tenor | Latest2026-07-27 | 1m ago2026-06-26 | 2m ago2026-05-28 | 3m ago2026-04-28 | 4m ago2026-03-30 | 5m ago2026-02-27 | 6m ago2026-01-28 |
|---|---|---|---|---|---|---|---|
| 2Y | 4.77% | 4.50% | 4.51% | 4.28% | 4.38% | 3.84% | 4.10% |
| 10Y | 5.41% | 5.10% | 5.18% | 5.18% | 5.27% | 5.05% | 4.84% |
| 10Y − 2Y | +64 bp | +60 bp | +67 bp | +90 bp | +89 bp | +121 bp | +75 bp |
Yields by rating group
The same curve split by credit quality: 97 rated bonds across 3 rating bands, all maturities pooled. Median yield by band: AAA to AA- 4.95%, A+ to BBB- 5.37%, Speculative 6.06%.
Bonds in this curve
A selection of 30 of the 97 bonds behind this curve, spread across maturities.
| Issuer | Yield | Maturity | Coupon | ISIN |
|---|---|---|---|---|
| Shire Acquisitions Investments Ireland DAC | 4.78% | 2026-09-23 | 3.20% | US82481LAD10 |
| Roche Holding AG | 4.56% | 2027-01-28 | 2.38% | USU75000BL90 |
| Novartis | 4.36% | 2027-02-14 | 2.00% | US66989HAQ11 |
| CSL Finance PLC | 5.11% | 2027-04-27 | 3.85% | USG2584CAA48 |
| Teva Pharmaceutical Industries LTD | 5.28% | 2027-05-09 | 4.75% | US88167AAP66 |
| Rede D'or Finance S.A.R.L. | 6.05% | 2028-01-17 | 4.95% | USL7915RAA43 |
| Teva Pharmaceutical Industries LTD | 5.11% | 2028-03-01 | 6.75% | US88167AAK79 |
| Glaxosmithkline Capital | 4.41% | 2028-05-15 | 3.88% | US377372AN70 |
| Novartis | 4.64% | 2028-11-05 | 3.90% | US66989HAX61 |
| Roche Holding AG | 4.66% | 2029-03-08 | 4.79% | USU75000CJ36 |
| Novartis | 4.63% | 2029-03-16 | 4.10% | US66989HBF47 |
| Laboratory Corp of America Holdings | 5.00% | 2030-04-01 | 4.35% | US50540RAZ55 |
| Glaxosmithkline Capital | 4.72% | 2030-04-15 | 4.50% | US377372AP29 |
| Fresenius SE & CO Kgaa | 5.49% | 2031-02-16 | 2.38% | USU3149FAB59 |
| Roche Holding AG | 4.82% | 2031-03-08 | 4.91% | USU75000CK09 |
| CSL Finance PLC | 5.30% | 2032-04-27 | 4.25% | USG2584CAC04 |
| Novartis | 4.95% | 2032-11-05 | 4.30% | US66989HAZ10 |
| Novartis | 5.03% | 2033-03-18 | 4.60% | US66989HBH03 |
| Genmab A/S & Genmab FIN LLC | 6.66% | 2033-12-15 | 7.25% | US37230JAB89 |
| Roche Holding AG | 5.12% | 2034-03-08 | 4.99% | USU75000CL81 |
| Laboratory Corp of America Holdings | 5.52% | 2034-10-01 | 4.80% | US50540RBB78 |
| Glaxosmithkline Capital | 5.27% | 2035-04-15 | 4.88% | US377372AQ02 |
| Novartis | 5.17% | 2035-11-05 | 4.60% | US66989HBA59 |
| Novartis | 5.23% | 2036-03-18 | 4.90% | US66989HBJ68 |
| Glaxosmithkline Capital | 5.47% | 2038-05-15 | 6.38% | US377372AE71 |
| Novartis | 5.62% | 2042-09-21 | 3.70% | US66989HAF55 |
| Glaxosmithkline Capital | 5.81% | 2043-03-18 | 4.20% | US377372AJ68 |
| Novartis | 5.79% | 2044-05-06 | 4.40% | US66989HAH12 |
| Novartis | 5.81% | 2050-08-14 | 2.75% | US66989HAS76 |
| Roche Holding AG | 5.81% | 2054-03-08 | 5.22% | USU75000CM64 |